JAKARTA - The state-owned company PT Phapros Tbk managed to record a net sales growth of 21 percent in the first semester of 2022 compared to the same period in 2021. This positive performance was driven by sales of Antimo products which began to increase again due to the revival of the tourism sector in Indonesia. In addition, the company's management began to focus on marketing innovative products in collaboration with other institutions more aggressively, either by educating the market or by a fairly massive campaign.
“Community mobilization, such as during the Lebaran homecoming season, is a positive sentiment towards Antimo's performance, which has a direct impact on the company's financial performance. In addition, this first semester's profit was also obtained from other Phapros flagship products, such as Becefort, Livron and products in the ethical sector (prescription drugs)," said Phapros President Director Hadi Kardoko when contacted in Jakarta (29/7).
In addition to sales, Phapros' positive performance in the first six months of 2021 is the decline in the company's long-term liability ratio by 6 percent compared to last year. In addition, in terms of profit for the current period, Phapros also posted an increase of 7 percent compared to 2021, and also an increase in earnings per share of 8 percent.
“We are very happy with this positive performance because it can provide the best results for investors and Phapros' parent company. We hope that in the second semester, we can record even higher growth and optimal performance compared to 2021. Through several new product innovation and efficiency efforts, including making commercial excellence, operational excellence, financial excellence and digitalization part of the main corporate strategy throughout 2022," he concluded. (LM)